Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial

详细信息    查看全文

• 作者：Francesco Giannini^a ; ^b ; ¹ ; Azeem Latib^a ; ^b ; ¹ ; ^{alatib@gmail.com} ; Richard J. Jabbour^a ; Charis Costopoulos^b ; Alaide Chieffo^a ; Mauro Carlino^a ; Matteo Montorfano^a ; Alberto Menozziⁿ ; Fausto Castriota^c ; Antonio Micari^d ; Alberto Cremonesi^e ; Francesco De Felice^f ; Alfredo Marchese^g ; Maurizio Tespili^h ; Patrizia Presbiteroⁱ ; Gregory A. Sgueglia^j ; Francesca Buffoli^k ; Corrado Tamburino^l ; Ferdinando Varbella^m ; Antonio Colombo^a ; ^b
• 关键词：Small coronary vessel disease ; Drug-eluting balloon ; Paclitaxel-eluting stent ; Diabetes mellitus
• 刊名：Cardiovascular Revascularization Medicine
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：18
• 期：1
• 页码：4-9
• 全文大小：303 K
• 卷排序：18

文摘

We evaluated the impact of diabetes on the efficacy of drug-eluting balloon (DEB) as compared to paclitaxel-eluting stent (PES) for the reduction of restenosis in small vessels according to the presence of diabetes in patients enrolled in the BELLO (Balloon Elution and Late Loss Optimization) trial. The diabetic group consisted of 74 patients (DEB = 39, PES = 35) and the nondiabetic group of 108 patients (DEB = 51, PES = 57). In patients with diabetes, angiographic restenosis and in-segment late loss was significantly lower with DEB as compared to PES (respectively, 6.3% vs. 25.0%; p = 0.039 and −0.013 ± 0.39 vs. 0.25 ± 0.53; p = 0.023), with no differences noted in nondiabetic patients. No difference in MACE were observed. Diabetes does not appear to have a negative impact on the efficacy of DEB in small vessels, which were associated with better angiographic outcomes at 6 months in this complex subgroup. Larger studies are needed to confirm these findings.